What question did this study set out to answer?

This study aims to investigate the role of PDE4D in myocardial ischemia-reperfusion injury and its regulation by METTL14-mediated m6A modification.

April 25, 2026Open Access

PDE4D Mediates the Cardiac Ischemia Reperfusion Injury and Is m6A Modified by METTL14

Puntos clave

This study aims to investigate the role of PDE4D in myocardial ischemia-reperfusion injury and its regulation by METTL14-mediated m6A modification.
Identified PDE4D as a promoter of myocardial I/R injury
Explored METTL14's role in N6-methyladenosine modification of PDE4D mRNA
Examined the regulatory relationship involving IGF2BP1.
PDE4D expression promotes cardiomyocyte apoptosis.
METTL14 modifies PDE4D mRNA and enhances its stability via IGF2BP1.
Targeting the METTL14/IGF2BP1/PDE4D axis may reduce cardiac I/R injury.

Resumen

Current therapies for cardiac ischemia-reperfusion (I/R) injury remain insufficient.This study identifies PDE4D as a novel promotor of myocardial I/R injury, addressing the unmet need for new therapeutic targets.We further reveal that METTL14-mediated N6methyladenosine modification stabilizes PDE4D mRNA via the reader IGF2BP1, a previously unknown regulatory axis.Scientifically, this uncovers a new epitranscriptomic mechanism controlling cardiomyocyte apoptosis.Clinically, targeting the METTL14/IGF2BP1/PDE4D axis could offer a promising strategy for mitigating cardiac I/R injury.

Me gusta

Guardar

Ver artículo completo